Actuate Therapeutics, Inc. Common stock (ACTU) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Actuate Therapeutics, Inc. Common stock (ACTU) closed at USD 0.43 on 2026-10-14, a change of -93.6 % over the past year, with a market capitalization of USD 12M.

Actuate Therapeutics, Inc. Common stock recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Actuate Therapeutics, Inc. Common stock key figures

Previous close

USD 0.43 (2026-10-14)

1-year change

-93.6 %

Market cap

USD 12M

Enterprise value

USD 7.58M

P/E ratio (trailing)

-0.58

P/E ratio (forward)

-0.75

EPS (trailing)

-0.87

EPS (forward)

-0.66

PEG ratio

n/a

Price to book

12.19

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.60

Employees

12

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Actuate Therapeutics, Inc. Common stock

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Actuate Therapeutics, Inc. Common stock and compare it with other stocks.